Article
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
Journal of the National Cancer Institute - 5 Sept 2007
Hoskins Janelle M, Goldberg Richard M, Qu Pingping, Ibrahim Joseph G, McLeod Howard L
Abstract excerpt
The Food and Drug Administration and Pfizer changed the package insert for irinotecan to include a patient's UGT1A1*28 genotype as a risk factor for severe neutropenia on the basis of the findings of four pharmacogenetic studies, which found that irinotecan-treated patients who were homozygous for the UGT1A1*28 allele had a greater risk of hematologic toxic effects than patients who had one or two copies of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.